| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/03/2011 | CA2528920C Cyclo(hetero)alkenyl compounds useful for treating pain |
| 05/03/2011 | CA2500852C Packaged antimicrobial medical device and method of preparing same |
| 05/03/2011 | CA2495886C Effervescent compositions comprising bisphosphonates and methods related thereto |
| 05/03/2011 | CA2494155C Arginine silicate inositol complex and use thereof |
| 05/03/2011 | CA2489824C Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
| 05/03/2011 | CA2484340C 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 05/03/2011 | CA2477879C Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect |
| 05/03/2011 | CA2476343C 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors |
| 05/03/2011 | CA2473988C Drechsleranol derivatives, method for the production and use thereof |
| 05/03/2011 | CA2473026C 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| 05/03/2011 | CA2469649C Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| 05/03/2011 | CA2467517C Substituted benzoxazoles and analogues as estrogenic agents |
| 05/03/2011 | CA2458974C Derivatives of uk-2a as fungicides |
| 05/03/2011 | CA2458626C Lipid derivatives of aminoglycosides |
| 05/03/2011 | CA2456507C Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander |
| 05/03/2011 | CA2443632C Timed pulse release composition |
| 05/03/2011 | CA2440438C Heterocyclic compounds |
| 05/03/2011 | CA2440091C Prodrugs of anticancer agents employing substituted aromatic acids |
| 05/03/2011 | CA2439709C Aryl and heteroaryl urea chki inhibitors for use as radiosensitizers and chemosensitizers |
| 05/03/2011 | CA2438848C Compositions for delivering bisphosphonates |
| 05/03/2011 | CA2438480C Glucocorticoid receptor modulators |
| 05/03/2011 | CA2438085C Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids |
| 05/03/2011 | CA2425933C Combination of catechin and quercetin for pharmaceutical or dietary use |
| 05/03/2011 | CA2421109C Efficient method for producing compositions enriched in anthocyanins |
| 05/03/2011 | CA2415010C Propane-1,3-dione derivatives useful as gnrh receptor antagonist |
| 05/03/2011 | CA2400778C Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
| 05/03/2011 | CA2400394C 9-alkylamino-1-nitroacridine derivatives |
| 05/03/2011 | CA2378586C Replication-competent anti-cancer vectors |
| 05/03/2011 | CA2347066C Isolated nucleic acid molecules which encode t cell inducible factors (tifs), the proteins encoded, and uses thereof |
| 05/03/2011 | CA2346564C Oxaliplatinum preparation packaging |
| 05/03/2011 | CA2342966C Gene alteration in the gene for the gbeta3 subunit of the human g protein |
| 05/03/2011 | CA2341503C Probiotic, lactic acid-producing bacteria and uses thereof |
| 05/03/2011 | CA2328485C Humanized antibodies that recognize verotoxin ii and cell line producing same |
| 05/03/2011 | CA2262525C Methods of treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors |
| 05/03/2011 | CA2246297C Use of an anti-human tnf-alpha monoclonal antibody in the manufacture of a therapeutic formulation for treating a thrombotic disorder |
| 05/03/2011 | CA2174961C Desferrioxamine oral delivery system |
| 04/29/2011 | CA2741429A1 Process for preparing chlorins and their pharmaceutical uses |
| 04/29/2011 | CA2708489A1 Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer |
| 04/28/2011 | WO2011050357A2 Protein arginine deiminase inhibitors as novel therapeutics for rheumatoid arthritis and cancer |
| 04/28/2011 | WO2011050353A1 Method for treating androgen receptor positive cancers |
| 04/28/2011 | WO2011050325A1 Compositions for treatment of cystic fibrosis and other chronic diseases |
| 04/28/2011 | WO2011050323A1 Compounds and methods for treating bacterial infections |
| 04/28/2011 | WO2011050319A2 Inhibiting the deleterious effect of anthracyclines |
| 04/28/2011 | WO2011050302A2 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment |
| 04/28/2011 | WO2011050284A1 Pyrazolylpyridine antiviral agents |
| 04/28/2011 | WO2011050245A1 Bicyclic heteroaryls as kinase inhibitors |
| 04/28/2011 | WO2011050220A1 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| 04/28/2011 | WO2011050210A1 Methods and compositions for cell-proliferation-related disorders |
| 04/28/2011 | WO2011050206A2 Compositions and methods for the treatment of sinonasal disorders |
| 04/28/2011 | WO2011050202A1 Fused heterocyclic compounds as orexin receptor modulators |
| 04/28/2011 | WO2011050200A1 Fused heterocyclic compounds as orexin receptor modulators |
| 04/28/2011 | WO2011050198A1 Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| 04/28/2011 | WO2011050196A2 Method for treating herpes virus infection |
| 04/28/2011 | WO2011050192A1 Modulation of axon degeneration |
| 04/28/2011 | WO2011050180A1 Novel dosing regimen and method of treatment |
| 04/28/2011 | WO2011050178A2 Targeted prdm gene or protein modulation therapeutic agents |
| 04/28/2011 | WO2011050175A1 Crystalline pharmaceutical and methods of preparation and use thereof |
| 04/28/2011 | WO2011050163A1 Method of preventing type 1 diabetes |
| 04/28/2011 | WO2011050160A1 Pharmaceuticals, compositions and methods of making and using the same |
| 04/28/2011 | WO2011050159A1 Compositions and processes |
| 04/28/2011 | WO2011050158A1 Anti-drug vaccines |
| 04/28/2011 | WO2011050146A1 Chemical compounds |
| 04/28/2011 | WO2011050126A1 Method for treating sepsis or septic shock |
| 04/28/2011 | WO2011050120A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| 04/28/2011 | WO2011050102A1 Dermatologic and cosmetic compositions |
| 04/28/2011 | WO2011050099A2 Therapeutic composition |
| 04/28/2011 | WO2011050095A2 Prevention and treatment of post-operative cognitive dysfunction (pocd) |
| 04/28/2011 | WO2011050063A1 2-substituted-ethynylthiazole derivatives and uses of same |
| 04/28/2011 | WO2011050054A2 Coumarin compounds as receptor modulators with therapeutic utility |
| 04/28/2011 | WO2011050030A1 Alpha adrenergic receptor modulators |
| 04/28/2011 | WO2011050018A1 Compositions and methods for controlling pupil dilation comprising phentolamine |
| 04/28/2011 | WO2011050016A1 Akt inhibitors |
| 04/28/2011 | WO2011050000A2 Single molecule nucleic acid nanoparticles |
| 04/28/2011 | WO2011049988A2 Indazoles to treat flaviviridae virus infection |
| 04/28/2011 | WO2011049987A2 Azaindazoles to treat flaviviridae virus infection |
| 04/28/2011 | WO2011049979A2 Injectable formulations for intra- articular or peri-articular administration |
| 04/28/2011 | WO2011049971A1 Boron-containing small molecules as antiprotozoal agents |
| 04/28/2011 | WO2011049958A2 Modulation of gel temperature of poloxamer-containing formulations |
| 04/28/2011 | WO2011049954A2 Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders |
| 04/28/2011 | WO2011049948A2 Neuroprotection and myelin repair using nestorone® |
| 04/28/2011 | WO2011049946A1 Combination cancer therapy with hsp90 inhibitory compounds |
| 04/28/2011 | WO2011049943A1 Method and kit for gastro-intestinal cleansing |
| 04/28/2011 | WO2011049917A1 Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| 04/28/2011 | WO2011049908A2 Bismacrokyclic compounds as hepatitis c virus inhibitors |
| 04/28/2011 | WO2011049825A1 Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| 04/28/2011 | WO2011049792A1 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis |
| 04/28/2011 | WO2011049737A1 Novel compositions for preventing and/or treating lysosomal storage disorders |
| 04/28/2011 | WO2011049736A1 Novel compositions for preventing and/or treating degenerative disorders of the central nervous system |
| 04/28/2011 | WO2011049731A1 Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| 04/28/2011 | WO2011049722A1 PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS |
| 04/28/2011 | WO2011049706A1 Orally transformable tablets |
| 04/28/2011 | WO2011049704A1 Antofine and cryptopleurine derivatives as anticancer agents |
| 04/28/2011 | WO2011049680A1 Cryosensitizing agents for enhancement of cryoablation |
| 04/28/2011 | WO2011049677A1 Compounds and compositions as tlr activity modulators |
| 04/28/2011 | WO2011049659A2 Novel use and method of rapamycin to treat toxic shock |
| 04/28/2011 | WO2011049629A2 Methods of making and using compositions comprising flavonoids |
| 04/28/2011 | WO2011049547A1 Method for wetting a powder containing benzoyl peroxide |
| 04/28/2011 | WO2011049539A1 Compositions comprising a corticosteroid, a beta2 agonist as well as cromoglicic acid or ndeocromil |
| 04/28/2011 | WO2011049520A1 Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 1 1 betahsd1 |
| 04/28/2011 | WO2011049484A1 Antioxidant |